Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
AssigneeErasmus Universiteit Rotterdam
InventorsCarel A. Van Baalen, Albertus D.M.E. Osterhaus
Life of this patent
Estimating the term…
Abstract
The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favorable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
Claims14
A method of treatment of a host, which comprises:
- stimulating in the host a specific cytotoxic T-cell response which is specific for the Rev and/or Tat proteins of the immunodeficiency virus.
A method of treatment of a host, which comprises:
- selectively stimulating a protective Rev and/or Tat protein-specific cytotoxic T-cell response in said host.
At least one cytotoxic T-cell epitope selected from the Rev and Tat proteins of HIV or a vector encoding the at least one cytotoxic T-cell epitope when used as a medicament.
Dependencies are inferred from the claim text.